Herein, our findings were in harmony and elucidated that Ad-ΔB/TRAIL and Ad-ΔB/IL-12 combination treatment was associated with a clear reduction in the intratumor expression of VEGF, CD31-positive cells, and in the microvessel density than the effects mediated by Ad-ΔB alone; suggesting a co-operative interaction between the administered OAds and their delivered TRAIL and IL-12 genes in halting tumor-driven angiogenesis and neovascularization. This evidence concerns the gene VEGFA and neoplasm.